Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Investigator Initiated, Randomized, Double-blinded, Placebo-controlled Clinical Trial to Evaluate the Safety, Immunogenicity and Efficacy of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) in Adults Aged 18 Years and Older

NCT05679466 is registered in ClinicalTrials.gov with Yu Qin as lead sponsor.

NCT NCT05679466
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05679466 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Investigator Initiated, Randomized, Double-blinded, Placebo-controlled Clinical Trial to Evaluate the Safety, Immunogenicity and Efficacy of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) in Adults Aged 18 Years and Older
Lead sponsor
Yu Qin
Phase
Phase 1
Overall status
Unknown status
Start date
December 27, 2022
Completion date
December 31, 2023
Enrollment
3,300 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prevention of covid-19 caused by sars-cov-2